92 results about "Airway hyperresponsiveness" patented technology

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and / or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

Disclosed is a method to reduce airway hyperresponsivesness in an animal by the direct delivery to the lungs of aerosolized antibodies against T cell receptors. The method is particularly useful for treating airway hyperresponsiveness associated with allergic inflammation, is effective at extremely low doses of antibody, and does not have a substantial effect on the peripheral immune system.

Described herein are methods and compositions for treatment of inflammation, such as inflammation in lung and / or airway tissue, including asthma Innate lymphoid cells (ILCs), such as type 2 ILC2s, are herein described as capable of IL-33 signaling activation, leading to airway hyperresponsiveness (AHR) and inflammation. Further described is the hereto unknown discovery that ICOS-ligand is expressed in ILC2s, that ICOS binding of ICOS to ICOS-ligand is required for its function in ILC2s, and that while IL-33 treatment induces AHR in control mice, IL-33 cannot induce AHR in mice receiving treatment via anti-ICOS-ligand antibodies. These results suggest new methods and compositions targeting ICOS and ICOS-ligand, such as dual specific antibodies that recognize ICOS and ICOS-ligand, an expression profile unique to ILC2s.

The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.

This invention relates to a method to protect a mammal from a disease associated with an inflammatory response, and in particular, from an inflammatory disease characterized by eosinophilia, airway hyperresponsiveness and / or a Th2-type immune response. The method includes administration of a heat shock protein to a mammal having such a disease. Formulations useful in the present method are also disclosed.

The present invention provides methods to protect a subject from a respiratory disorder involving an airway obstructive disease such as asthma or chronic obstructive pulmonary disease. Provided are methods to protect a subject from an airway obstructive disease using gene therapy. Methods are provided for supplying FoxA2 function to cells of the lung and airway, such as smooth muscle and epithelial cells, by FoxA2 gene therapy. The FoxA2 gene, a modified FoxA2 gene, or a part of the gene may be introduced into the cell in a vector such that the gene remains extrachromosomal or may be integrated into the subjects chromosomal DNA for expression. These methods provide for administering to a subject in need of such treatment a therapeutically effective amount of a FoxA2 gene, or pharmaceutically acceptable composition thereof, for overexpressing the FoxA2 gene. Such methods of expressing the administered FoxA2 gene in the lungs and airway provide for: (1) preventing or alleving bronchial hyperresponsiveness; (2) preventing or alleving of an airway obstructive disease, e.g., bronchial hyperreactivity, airway hyperresponsiveness, asthma or chronic obstructive pulmonary disorder (“COPD”); (3) reducing the airway resistance response to inhaled natural or synthetic bronchoconstrictors or allergens or to exercise; and (4) enhancing responsiveness (relaxation) of airway tissues to β-agonists.

Disclosed herein are antisense compounds and methods for decreasing CD40. Examples of disease conditions that can be ameliorated with the administration of antisense compounds targeted to CD40 include hyperproliferative disorders, graft versus host disease (GVHD), graft rejection, asthma, airway hyperresponsiveness, chronic obstructive pulmonary disease (COPD), multiple sclerosis (MS), systemic lupus erythematosus (SLE), and certain forms of arthritis.

The present invention relates an agent comprising FGF2(Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor(bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease(COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.

A method for the treatment and / or prophylaxis of an animal having a respiratory disease or condition associated with airway hyperresponsiveness, eosinophilia, neutrophilia, leukocytes or overproduction of mucus and / or with the expression of integrin α4 comprising administering to the animal a composition comprising from. 0.001 to 1000 μg per kg body weight of the animal of an antisense compound targeted to a nucleic acid molecule encoding integrin α4.

The invention belongs to the technical field of medicines, and provides a propranolol hydrochloride (PPL.HCL) gel which can be externally used for treating infant superficial hemangioma. The propranolol hydrochloride gel is mainly prepared from propranolol hydrochloride, gel matrix, a percutaneous penetration enhancer, a preservative, a humectant and the like. By using the propranolol hydrochloride gel, adverse reactions such as decreased heart rate, cyanosis, airway hyperresponsiveness, shortage of granular leukocytes, diarrhoea, sleep change and blood sugar reduction caused by orally taking propranolol by hemangioma patients can be reduced and even avoided, and the problems that oral dosage is not easy to control, infants inconveniently take medicines and the like are solved.

The invention belongs to the pharmaceutical field, relates to a novel medicinal use of calycosin-7-glucoside and especially relates to a use of calycosin-7-glucoside in preparation of drugs for treating asthma and especially for treating allergic asthma. The results of an in-vivo animal experiment and an in-vitro CD4+T cell culture experiment show that calycosin-7-glucoside has effects on an ovalbumin-induced mouse asthma model and CD4+T cells isolated from spleen, and can significantly reduce airway hyperresponsiveness of asthmatic mice, inhibit airway inflammation, reduce the number of inflammatory cells in an alveolar lavage fluid, inhibit chemokine secretion, promote Th1 cell differentiation, inhibit IL-17A, promote IFN-gamma and IL-10 secretion and inhibit NF-kappa B activation. The calycosin-7-glucoside can be used as a single ingredient for preparation of drugs for treating asthma or allergic asthma.

Disclosed are novel inhibitors of the alternative complement pathway and particularly, novel anti-factor B antibodies. Also disclosed is the use of such inhibitors to reduce or prevent airway hyperresponsiveness and / or airway inflammation by selectively inhibiting the alternative complement pathway, thereby treating diseases in which such conditions play a role. Also disclosed is the use of such inhibitors to reduce or prevent other diseases and conditions, including ischemia-reperfusion injury, by inhibition of the alternative complement pathway.

This invention relates to a method to protect a mammal from a disease associated with an inflammatory response, and in particular, from an inflammatory disease characterized by eosinophilia, airway hyperresponsiveness and / or a Th2-type immune response. The method includes administration of a heat shock protein to a mammal having such a disease. Formulations useful in the present method are also disclosed.

The present invention provides the use of formulation with surfactant protein-D (SP-D) in the modulation of activity of human eosinophils derived from hypereosinophilic patients to an increased activation state and increased apoptosis. Accordingly the utility of the invention can be extended in human subjects in resolution of eosinophilic inflammations in related diseases and disorders like neuromuscular and respiratory diseases with eosinophilia other than airway-hyperresponsiveness, allergy and asthma, hypereosinophilic leukemias, hypereosinophilc syndromes (rare hematological diseases), skin diseases like eosinophilia-Myalgia syndrome, eosinophilic fascitis, capillary leak syndromes (IL-2), Churg-Strauss syndrome, toxic oil syndrome, parasitosis, etc., where a large number of stimulated eosinophils accumulate and release a series of growth factors, cytokines, chemokines, bioactive lipid mediators, toxic oxygen metabolites.

The invention relates to a method of assessing airway variability in airway responsiveness or asthma by measuring the variation of resistance (Rrs) by a forced oscillation technique utilizing either a single or a plurality of input frequencies during a plurality of respiratory cycles of a patient; calculating the statistical variability of the Rrs for the patient; and, correlating the statistical variability of the Rrs of the patient to a standard curve to quantify the degree of asthma of the patient. The invention also enables the effectiveness of a bronchoactive agent to be measured.

The present invention discloses a class of quinine compounds and pharmaceutically acceptable salts, solvates, prodrugs or optical isomers thereof. Also disclosed in the present invention are that the above compounds have a selective antagonistic effect on the receptor subtypes of M1 and M3, but have no significant effect on M2 receptor subtype, and the above compounds are characterized by rapid action, long-lasting efficacy, and low toxic and side-effects when used to treat rhinitis, post-cold rhinitis, chronic trachitis, airway hyperresponsiveness, asthma, chronic obstructive pulmonary diseases, cough, urinary incontinence, frequent urination, unstable bladder syndrome, bladder spasms, bladder inflammation and gastrointestinal diseases such as irritable bowel syndrome, spastic colitis, as well as duodenal and gastric ulcers.

The present invention relates an agent comprising FGF2 (Fibroblast Growth Factor-2 or basic Fibroblast Growth Factor(bFGF)) as an effective ingredient for treatment or prevention of Asthma and Chronic Obstructive Pulmonary Disease(COPD). Also, The present invention relates Th1 asthma and COPD mouse animal model induced by Ovalbumin and double strand RNA. The therapeutic agent comprising FGF2 of the present invention can be used for treatment or prevention for airway fibrosis, airway inflammation, airway hyperresponsiveness, airway remodeling, asthma and COPD. Also, Th1 asthma and COPD mice animal model induced by Ovalbumin and double strand RNA can be used for development of therapeutic agent for asthma and COPD.

The invention relates to an improved mustard plaster applied on an acupuncture point for intervention treatment of a chronic obstructive pulmonary disease and a preparation method and an application thereof, belonging to the technical field of treatment through combination of traditional Chinese medicine and Western medicine. The medicament for intervention treatment of the chronic obstructive pulmonary disease is characterized by comprising the following raw materials in parts by weight: 1-2 parts of manchurian wildginger, 1-1.5 parts of white mustard seed, 1-1.5 parts of gansui root, 0.5-1.5 parts of rhizoma corydalis, 0.2-0.6 part of cassia bark, 0.2-0.6 part of flos caryophyllata, 0.1-0.3 part of Szechuan pepper, 0.1-0.2 part of borneol, 0.003-0.005 part of anisodamine, 0.003-0.005 part of chlorpheniramine and 3-5 parts of fresh ginger juice. Compared with the prior art, the medicament provided by the invention has the following advantages: combining the traditional Chinese medicine with the Western medicine, respectively playing the effects, treating both manifestation and root cause of the disease, being convenient for administration, being fast in onset of action and having small side effects. The medicament can effectively reduce airway hyperresponsiveness, control occurrence and development of the condition of the disease and alleviate clinical symptoms.

The invention in particular relates to a traditional Chinese medicine composition for treating respiratory tract infection and inflammation and a preparation method thereof. The traditional Chinese medicine composition is prepared mainly from the following medicinal raw materials in parts by weight: 4-13 parts of tenuifolia, 4-13 parts of Chinese parsnip root, 4-13 parts of radix bupleuri, 4-18 parts of scutellaria baicalensis, 4-13 parts of fructus forsythiae, 6-18 parts of sculellaria barbata, 4-18 parts of bighead atractylodes rhizome, 3-13 parts of rhizoma anemarrhenae, 6-13 parts of platycodon grandiflorum, 6-13 parts of pericarpium citri reticulatae, 4-8 parts of liquorice and 6-18 parts of loquat leaves. The medicine composition integrates the functions of relieving superficies syndrome with pungent and warm natured medicinal materials, relieving superficies syndrome with pungent and cold natured medicinal materials, clearing away heat and toxic materials, tonifying spleen, reducing phlegm, opening the inhibited lung-energy and relieving a cough and consider various aspects. By utilizing the compatibility of the above medicinal raw materials, immunity can be adjusted, infection can be quickly controlled, the purpose of rapid curing airway hyperresponsiveness inflammation is reached, and the traditional Chinese medicine composition is suitable for contemporary physique and pathogenesis characteristics of respiratory tract infection and inflammation. The traditional Chinese medicine composition focuses on curing underlying problem, can take effect quickly and is low in cost.

The invention provides a traditional Chinese medicine composition for treating bronchial asthma in the acute-outbreak period. The traditional Chinese medicine composition comprises the following raw materials: fructus corni, semen lepidii, white mulberry root-bark, radix scutellariae, cortex lycii radicis, corydalis tuber, wadalee-gum-tree, dried ginger, iris tectorum maxim, aristolochia, fewflower lysionotus herb, celandine, saffron, American ginseng, cinnamon, physochlaina macrophylla, rhodiola, acanthopanax, changium smyrnioide, sea-buckthorn, japanese inula herb, salvia miltiorrhiza, bamboo shavings, lumbricus, pinellia ternate, cassia twig and garden balsam. The traditional Chinese medicine composition has the advantages of being capable of inhibiting the inflammatory reaction, reducing the airway hyperresponsiveness state, improving the micro-circulation, improving the pulmonary ventilation function and adjusting the immune function in the acute-outbreak period of the bronchial asthma; and compared with western medicines, the traditional Chinese medicine composition has the advantages of being capable of better improving the life quality of asthma patients and reducing the usage amount of glucocorticoids, having little toxic and side effects without drug tolerance and being low in cost.

Disclosed is a method for regulation of airway hyperresponsiveness by modulating the action of γδ T cells in a patient. Also disclosed are methods for identifying compounds that regulate airway hyperresponsiveness by modulating γδ T cell action.

Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-α, airway hyperresponsiveness, and / or pulmonary inflammation.

Disclosed herein are compounds, compositions and methods for modulating the expression of IL-4R alpha in a cell, tissue or animal. Also provided are methods of target validation. Also provided are uses of disclosed compounds and compositions in the manufacture of a medicament for treatment of diseases and disorders related to expression of IL 4R-α, airway hyperresponsiveness, and / or pulmonary inflammation.

The present invention provides methods and compositions for inhibition of Airway Hyperresponsiveness (“AHR”) by deleting, inactivating or inhibiting a subset of innate γδ T cells, alone or in conjunction with the inhibition of Natural Killer T (“NKT”) cells. The methods comprise selective leukophoresis to remove the γδ T cells from the individual's blood or administration of an agent that selectively targets and inhibits or inactivates the γδ T cells. The methods of the present invention can be used to treat AHR in a variety of different ailments, including allergen-induced conditions or respiratory conditions and diseases.